VIR BIOTECHNOLOGY, INC. (VIR) News
Filter VIR News Items
VIR News Results
|Loading, please wait...|
VIR News Highlights
- For VIR, its 30 day story count is now at 29.
- Over the past 29 days, the trend for VIR's stories per day has been choppy and unclear. It has oscillated between 1 and 8.
- The most mentioned tickers in articles about VIR are GSK, BA and BEAT.
Latest VIR News From Around the Web
Below are the latest news stories about Vir Biotechnology Inc that investors may wish to consider to help them evaluate VIR as an investment opportunity.
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
– Significant progress made increasing global patient access to sotrovimab; approximately 1.7 million doses sold to date – – $917.2 million of sotrovimab collaboration revenue recognized in 2021 – – Multiple commercial and clinical value drivers expected across the portfolio in 2022 – SAN FRANCISCO, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the fourth quarter and full year ended December 31, 2021.
Avid Bioservices (CDMO) is set to provide updates on its CDMO business and other such developments when it reports earnings results for third quarter of fiscal 2022.
Vir Biotechnology, Inc. ( NASDAQ:VIR ) shareholders will have a reason to smile today, with the analysts making...
Vir Biotechnology, Inc. (VIR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ProQR (PRQR) lead candidate sepofarsen did not meet primary and secondary goals in phase II/III study.
Gilead's (GILD) Veklury (remdesivir) retains antiviral activity against Omicron, Delta and other emergent SARS-CoV-2 variants in multiple in vitro studies.
No summary available.
LONDON: An antibody-based COVID-19 therapy developed by GSK and Vir Biotechnology retains neutralising activity against the emerging BA.2 form of the Omicron coronavirus variant, Vir said on Thursday, citing data from lab work. The US company said it expected to release preprint data in the coming week, with live virus data to follow. Based on pseudovirus and extensive pharmacokinetic data, the company said it believed the 500 mg dose of sotrovimab is sufficient to retain activity against the BA.2 variant, which is in line with all other variants of concern and interest. The monoclonal antibody therapy, sotrovimab, is authorised for emergency use in the United States. GSK''s COVID-related sales close to $2bn, profit boost to wane in 2022 The companies are sharing the latest data with gl...
An antibody-based COVID-19 therapy developed by GSK and Vir Biotechnology retains neutralising activity against the emerging BA.2 form of the Omicron coronavirus variant, Vir said on Thursday, citing pre-clinical data.
Vir Biotechnology to Provide Corporate Update and Report Fourth Quarter and Full Year 2021 Financial Results on February 24, 2022
SAN FRANCISCO, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the fourth quarter and full year ended December 31, 2021, on Thursday, February 24, 2022.